Warning letter
Tubilux Pharma Spa: warning letter of Jul 6, 2017
FDA warning letter 523119 · Center for Drug Evaluation and Research
Key facts
| Reference number | 523119 |
|---|---|
| Company | Tubilux Pharma Spa |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jul 6, 2017 |
| Posted date | Jul 18, 2017 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.63, 211.160(b) |
| Inspection city | Pomezia |
| Inspection start date | Dec 1, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: